New in 2024

Here's What Was New for the 2024 Meeting!

Investor & Biopharma Partnerships Evening - Free to Attend

After a challenging year for cell therapy investment, this session spotlighted big pharma, VC and investor perspectives on the current market and opportunities, stemming a conversation on how investment into this promising space can be reinvigorated.

Speakers:

David Fontana
Chief Business & Operating Officer
Umoja Biopharma
Chris Moore
Senior Vice President & General Counsel
Umoja Biopharma
Stefano Quintini
Partner, Technology Transactions, Industry Co-Lead, Healthtech & Life Sciences
Fenwick & West
Miguel Forte
President Elect | Entrepreneur in Residence
ISCT | AdBio Partners

 

C-Level Think Tank - Invitation Only

Saw an exclusive opportunity for top C-level executives to collaborate and discuss the most pressing challenges the CAR-TCR community are facing in Europe

New Topics Included:

CAR-T Applications in Autoimmunity

CAR-T Applications in Autoimmunity

Expanding clinical access and pursuing a huge new population pool by harnessing CAR-T or CAR-Treg therapy to treat autoimmunity. Turbocharging durable efficacies, reviewing safety considerations, detecting surrogate biomarkers, and evaluating indications to maximise clinical outcome with Cabaletta Bio, Kyverna Therapeutics, AstraZeneca, Novartis, and Quell Therapeutics.

Non-Viral Engineering

Non-Viral Engineering

Reviewing engineering efficiencies of non-viral methods, such as CRISPR, electroporation, LNP, and TALEN, and harnessing these novel approaches to armour cells against the TME, decrease vein-to-vein times, and cut costs of production with Cellectis, Genome Frontier Therapeutics, Anocca, Arsenal Bio, and T-CURX.

Point of Care Manufacturing

Point of Care Manufacturing

Reinventing turnaround times, cost of goods, and accessibility through a decentralised manufacturing model approach with pioneers, Tigen Pharma. This topic discussed site onboarding and regulatory considerations to understand how you can implement this novel system.

Discover New Clinical Data from Next Gen Programs

Discovery of New Clinical Data from Next Gen Programs!

Exploration of clinical updates and biomarker data from trials demonstrating durable efficacies across solid tumours (with Franco Locatelli and Immatics), allogeneic approaches (Cellectis, Caribou Bio), and autoimmune indications (Kyverna Therapeutics, ImmPACT Bio).

New Speaking Companies Included:

Impact Bio - Developing a Robust Target Discovery Platform to Uncover Highly Specific Antigens
Etcembly - Developing New Classes of Ultraprecision T-Cell Receptor Bispecific Immunotherapies
Glycostem - Harnessing Combination & Co-Stimulation Approaches to Boost Efficacy, Persistence & Improve Clinical Outcomes
Mnemo Therapeutics - Developing a Robust Target Discovery Platform to Uncover Highly Specific Antigens
T-Curx - Comparing Viral vs Non-Viral Engineering Methods
Tigen Pharma - Implementing & Managing a Point of Care Manufacturing Model to Reinvent Vein-to-Vein Times & Boost Accessibilty
Carisma Therapeutics - Engineering Macrophages for Cancer Immunotherapy: CAR-M & Beyond
Avesya - Development of a First in Class CAR T-Cell Investigational Product for the Treatment of r/r AML